Barclays Capital Reiterates Overweight on Watson Pharmaceuticals Incorporated (WPI)
Watson Pharmaceuticals Incorporated traded down 1.21% on Wednesday, hitting $71.58. Watson Pharmaceuticals Incorporated has a 1-year low of $55.00 and a 1-year high of $76.47. The company has a market cap of $9.120 billion and a price-to-earnings ratio of 34.05.
Watson Pharmaceuticals Incorporated last released its earnings data on Monday, April 30th. The company reported $1.64 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.60 by $0.04. The company’s quarterly revenue was up 73.9% on a year-over-year basis. Analysts expect that Watson Pharmaceuticals Incorporated will post $1.34 EPS next quarter.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bank of America (NYSE: BAC) raised their price target on shares of Watson Pharmaceuticals Incorporated to $93.00 in a research note to investors on Wednesday. Separately, analysts at Needham & Company reiterated a “hold” rating on shares of Watson Pharmaceuticals Incorporated in a research note to investors on Wednesday. Finally, analysts at Wells Fargo & Co. (NYSE: WFC) upgraded shares of Watson Pharmaceuticals Incorporated from a “market perform” rating to an “outperform” rating in a research note to investors on Thursday, May 24th.
Watson Pharmaceuticals, Inc. (Watson) is an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products.